Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Chronic Idiopathic Constipation (CIC) Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Lubiprostone
      • 1.3.3 Linaclotide
      • 1.3.4 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Share by Application (2019-2025)
      • 1.4.2 Hospitals & Clinics
      • 1.4.3 Ambulatory Surgical Centres
      • 1.4.4 Long Term Care Centres
      • 1.4.5 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size
      • 2.1.1 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue 2014-2025
      • 2.1.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales 2014-2025
    • 2.2 Chronic Idiopathic Constipation (CIC) Drugs Growth Rate by Regions
      • 2.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers
      • 3.1.1 Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Chronic Idiopathic Constipation (CIC) Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Chronic Idiopathic Constipation (CIC) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Chronic Idiopathic Constipation (CIC) Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Chronic Idiopathic Constipation (CIC) Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Chronic Idiopathic Constipation (CIC) Drugs Market
    • 3.6 Key Manufacturers Chronic Idiopathic Constipation (CIC) Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Lubiprostone Sales and Revenue (2014-2019)
      • 4.1.2 Linaclotide Sales and Revenue (2014-2019)
      • 4.1.3 Others Sales and Revenue (2014-2019)
    • 4.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type
    • 4.3 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type
    • 4.4 Chronic Idiopathic Constipation (CIC) Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Application

    6 United States

    • 6.1 United States Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Company
    • 6.2 United States Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Type
    • 6.3 United States Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Company
    • 7.2 European Union Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Type
    • 7.3 European Union Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Application

    8 China

    • 8.1 China Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Company
    • 8.2 China Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Type
    • 8.3 China Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Company
    • 9.2 Rest of World Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Type
    • 9.3 Rest of World Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Application
    • 9.4 Rest of World Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
      • 9.4.2 Rest of World Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Actavis
      • 10.1.1 Actavis Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.1.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.1.5 Actavis Recent Development
    • 10.2 Chugai Pharmaceutical
      • 10.2.1 Chugai Pharmaceutical Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.2.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.2.5 Chugai Pharmaceutical Recent Development
    • 10.3 Ferring International Center
      • 10.3.1 Ferring International Center Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.3.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.3.5 Ferring International Center Recent Development
    • 10.4 Synergy Pharmaceuticals
      • 10.4.1 Synergy Pharmaceuticals Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.4.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.4.5 Synergy Pharmaceuticals Recent Development
    • 10.5 Pfizer
      • 10.5.1 Pfizer Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.5.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.5.5 Pfizer Recent Development
    • 10.6 GlaxoSmithKline
      • 10.6.1 GlaxoSmithKline Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.6.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.6.5 GlaxoSmithKline Recent Development
    • 10.7 Roche Holding
      • 10.7.1 Roche Holding Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.7.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.7.5 Roche Holding Recent Development
    • 10.8 Sanofi
      • 10.8.1 Sanofi Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.8.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.8.5 Sanofi Recent Development
    • 10.9 Bayer
      • 10.9.1 Bayer Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.9.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.9.5 Bayer Recent Development
    • 10.10 Salix Pharmaceuticals
      • 10.10.1 Salix Pharmaceuticals Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Chronic Idiopathic Constipation (CIC) Drugs
      • 10.10.4 Chronic Idiopathic Constipation (CIC) Drugs Product Introduction
      • 10.10.5 Salix Pharmaceuticals Recent Development
    • 10.11 Sucampo Pharmaceuticals
    • 10.12 Ironwood Pharmaceuticals
    • 10.13 Progenics Pharmaceuticals

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Chronic Idiopathic Constipation (CIC) Drugs Sales Channels
      • 11.2.2 Chronic Idiopathic Constipation (CIC) Drugs Distributors
    • 11.3 Chronic Idiopathic Constipation (CIC) Drugs Customers

    12 Market Forecast

    • 12.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Forecast by Type
    • 12.3 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Forecast by Application
    • 12.4 Chronic Idiopathic Constipation (CIC) Drugs Forecast by Regions
      • 12.4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of difficult, infrequent, or incomplete bowel movements.
      In 2019, the market size of Chronic Idiopathic Constipation (CIC) Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Chronic Idiopathic Constipation (CIC) Drugs.

      This report studies the global market size of Chronic Idiopathic Constipation (CIC) Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Chronic Idiopathic Constipation (CIC) Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Actavis
      Chugai Pharmaceutical
      Ferring International Center
      Synergy Pharmaceuticals
      Pfizer
      GlaxoSmithKline
      Roche Holding
      Sanofi
      Bayer
      Salix Pharmaceuticals
      Sucampo Pharmaceuticals
      Ironwood Pharmaceuticals
      Progenics Pharmaceuticals

      Market Segment by Product Type
      Lubiprostone
      Linaclotide
      Others

      Market Segment by Application
      Hospitals & Clinics
      Ambulatory Surgical Centres
      Long Term Care Centres
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Chronic Idiopathic Constipation (CIC) Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Chronic Idiopathic Constipation (CIC) Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Chronic Idiopathic Constipation (CIC) Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now